VIM and colorectal cancer: The COX‐2 selective antagonist celecoxib was revealed to prevent EMT‐mediated malignant transformation by modulating β‐catenin nuclear localization, the vimentin/E‐cadherin proportion and EMT‐TFs (Slug, Snail and ZEB1) in colorectal cancer cells and oral squamous cell carcinoma.495, 496